Drug or treatment

Ivonescimab clinical trials

• 62Clinical trials
• 1New in 30 days
• 21Countries

Newest trials

All recruiting trials (62)

• Ivonescimab with pemetrexed and platinum chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

  This study tests whether adding ivonescimab to standard pemetrexed plus platinum-based chemotherapy can help people with newly diagnosed advanced malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT07885319

• Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer

  This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07854600

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• Ivonescimab as first-line treatment for PD-L1 positive, driver gene-negative advanced NSCLC

  This real-world study tests whether Ivonescimab given as a first-line therapy helps patients with PD-L1 positive, driver gene-negative advanced NSCLC succeed with treatment and manage safety.

  Recruiting Guangdong Association of Clinical Trials · Guangzhou, Guangdong · NCT07696832

• Ivonescimab in advanced cutaneous angiosarcoma: a first look

  This Phase 2 pilot tests ivonescimab in adults with advanced or metastatic cutaneous angiosarcoma who have already had taxane-based chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07655570

• Trastuzumab Deruxtecan plus ivonescimab for HR+ HER2-low advanced breast cancer

  This study tests whether combining Trastuzumab Deruxtecan with ivonescimab can help people with HR-positive, HER2-low metastatic breast cancer after prior CDK4/6 inhibitor therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07647016

• AK138D1 alone or with Ivonescimab in advanced non-small cell lung cancer

  This study tests AK138D1 by itself or with Ivonescimab in adults with advanced non-small cell lung cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Akeso · Shanghai, Shanghai Municipality · NCT07623356

• Tepotinib plus Ivonescimab for MET exon 14–positive NSCLC

  This study tests whether a combination of tepotinib and ivonescimab is safe and helps people with MET exon 14–skipping non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07619339

• Risvutatug rezetecan with ivonescimab in adults with advanced solid tumors

  This study tests a new combination treatment to see if it is safe and potentially effective for adults with advanced solid cancers, including lung cancers.

  Recruiting at 4 sites Phase 1/2 GlaxoSmithKline · Los Angeles, California and 3 other locations · NCT07602855

• Ivonescimab after SBRT for early-stage NSCLC

  This study tests whether adding ivonescimab after standard SBRT helps people with early-stage non-small cell lung cancer.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07594522

• AMT-116 with AK112 in advanced NSCLC

  This study tests whether AMT-116 plus Ivonescimab (AK112) is safe and helpful for adults with advanced non-small cell lung cancer who can’t be cured with surgery or standard treatment.

  Recruiting Phase 1/2 Multitude Therapeutics Inc. · Guangzhou, Guangdong and 1 other locations · NCT07590531

• Ivonescimab with chemotherapy and stereotactic radiosurgery for NSCLC brain metastases

  This trial tests whether adding the experimental drug ivonescimab to standard chemotherapy and stereotactic radiosurgery helps people with non-small cell lung cancer that has spread to the brain.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535463

• Ivonescimab with datopotamab deruxtecan or osimertinib for EGFR‑mutant non‑small cell lung cancer

  This trial will test whether combining ivonescimab with datopotamab deruxtecan or with osimertinib is safe and helps people with metastatic EGFR‑mutant non‑small cell lung cancer who have already received third‑generation EGFR inhibitors and chemotherapy.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535437

• Ivonescimab treatment for people with leiomyosarcoma

  We will try ivonescimab in adults with advanced or unresectable leiomyosarcoma to see if it controls the cancer and causes few or mild side effects.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07516925

• Garsorasib and Ivonescimab with Chemo Before Surgery for KRAS G12C NSCLC

  This trial tests whether giving garsorasib followed by ivonescimab with chemotherapy before surgery helps people with resectable KRAS G12C-mutant NSCLC.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong,China · NCT07472478

• Chidamide plus Ivonescimab for advanced NSCLC with immune resistance and high YAP

  This phase II, single-arm study tests whether CHIDamide plus Ivonescimab can help adults with advanced NSCLC who have stopped responding to immunotherapy and have high YAP expression.

  Recruiting Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07412262

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• Advanced NSCLC with actionable mutations after targeted therapy and chemo: expanded Lung-MAP treatment

  This phase II trial tests whether sacituzumab govitecan alone, ivonescimab alone, or the combination of both can help people with advanced or recurrent NSCLC that has a targetable genetic change.

  Recruiting at 41 sites Phase 2 SWOG Cancer Research Network · Berkeley, California and 40 other locations · NCT07393555

• Ivonescimab with albumin‑paclitaxel and cisplatin before surgery for esophageal squamous cell carcinoma

  This trial tests whether adding ivonescimab to albumin‑paclitaxel and cisplatin before surgery helps people with resectable, locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 1/2 Tang-Du Hospital · Xi'an, Shannxi · NCT07385001

• Becotatug Vedotin with or without Immunotherapy before surgery for locally advanced head and neck cancer

  This trial tests Becotatug Vedotin alone or together with immune checkpoint inhibitors to see if pre-surgery treatment can improve outcomes for people with resectable locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07381075

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Ivonescimab with or without ligufalimab versus pembrolizumab as first-line treatment for recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma

  This study tests whether ivonescimab alone or with ligufalimab works as a first-line treatment for PD-L1‑positive recurrent or metastatic head and neck cancer, compared with pembrolizumab.

  Recruiting Phase 3 Groupe Oncologie Radiotherapie Tete et Cou · Le Havre · NCT07264075

• Ivonescimab combinations for first-line extensive-stage small cell lung cancer

  This test tries whether adding AK117 or cadonilimab to ivonescimab plus chemotherapy helps adults newly diagnosed with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 2 Akeso · Beijing, Beijing Municipality and 2 other locations · NCT07245446

• Ivonescimab plus chemotherapy before surgery for resectable esophageal squamous cell cancer

  This study tests whether giving Ivonescimab together with chemotherapy before esophageal cancer surgery helps patients see better outcomes than surgery alone.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07244978

• Ivonescimab for metastatic endocrine-refractory invasive lobular carcinoma (HR+ HER2− or triple-negative)

  This trial will test whether the experimental antibody ivonescimab can control tumor growth in adults with metastatic invasive lobular breast cancer that is endocrine-refractory and either HR-positive/HER2-negative or triple-negative.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07229417

• Ivonescimab versus bevacizumab with FOLFOX for first-line metastatic colorectal cancer

  This study tests whether ivonescimab combined with FOLFOX works as well as bevacizumab with FOLFOX for people starting first-line treatment for metastatic colorectal cancer.

  Recruiting at 243 sites Phase 3 Summit Therapeutics · Mobile, Alabama and 242 other locations · NCT07228832

• Ivonescimab given before surgery for high-risk localized clear cell kidney cancer

  This study tests whether giving ivonescimab before nephrectomy helps patients with high-risk localized clear cell renal cell carcinoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07226544

• Combination of YL201 and ivonescimab (AK112) for advanced solid tumors

  This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong · NCT07208773

• Ivonescimab with short-course hypofractionated radiotherapy for second-line esophageal squamous cell carcinoma

  This will try Ivonescimab plus a short course of higher‑dose radiotherapy as a second‑line option for adults (18–80) with locally advanced or metastatic esophageal squamous cell carcinoma who have failed first‑line therapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07188103

• Gemcitabine plus Ivonescimab for advanced NSCLC that progressed after immunotherapy

  This trial tests whether combining gemcitabine with ivonescimab can help people with advanced NSCLC whose cancer has grown after prior chemo-immunotherapy.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Baden and 7 other locations · NCT07158489

• Ivonescimab with paclitaxel and cisplatin before type A hysterectomy for Stage IB2/IIA1 (2–4 cm) cervical cancer

  This trial will test whether adding ivonescimab to paclitaxel and cisplatin before surgery helps women with 2–4 cm (Stage IB2 or IIA1) cervical cancer shrink tumors so they can have a less radical (type A) hysterectomy.

  Recruiting Phase 2 Obstetrics & Gynecology Hospital of Fudan University · Shanghai · NCT07130240

• Ivonescimab given before surgery for resectable stage II–IV head and neck cancer

  This trial tests whether giving ivonescimab before surgery helps people with resectable stage II–IV head and neck squamous cell carcinoma.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07094685

• Combination therapies for PD-1–resistant recurrent or metastatic nasopharyngeal cancer

  This trial will try four different treatment regimens in people with recurrent or metastatic nasopharyngeal cancer who no longer respond to anti‑PD‑1 therapy after prior platinum chemotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07070479

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

• Carboplatin and etoposide combined with ivonescimab for extensive-stage small cell lung cancer

  This test tries two doses of ivonescimab with carboplatin and etoposide in adults with newly diagnosed extensive-stage small cell lung cancer to find which dose works best and is safer.

  Recruiting at 13 sites Phase 2 PrECOG, LLC. · Miami, Florida and 12 other locations · NCT07057791

• Ivonescimab with carboplatin and docetaxel for early triple-negative breast cancer

  This trial will test whether adding ivonescimab to neoadjuvant carboplatin and docetaxel helps people with early-stage triple-negative breast cancer.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 3 other locations · NCT07017673

• Ivonescimab therapy for thymic carcinoma

  This trial tests whether ivonescimab can help adults with incurable, measurable thymic carcinoma who have had prior systemic therapy or cannot/will not have other treatments.

  Recruiting at 2 sites Phase 2 Jonsson Comprehensive Cancer Center · Davis, California and 4 other locations · NCT06980077

• Ivonescimab (anti-PD-1/VEGF bispecific) for previously treated metastatic colorectal cancer

  This trial will test whether ivonescimab can help control metastatic colorectal cancer in adults whose disease has progressed after prior treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06959550

• Ivonescimab plus chemotherapy, with or without AK117, for metastatic pancreatic cancer

  This trial will test whether adding the antibody Ivonescimab, with or without AK117, to standard chemotherapy helps people with metastatic pancreatic cancer live longer or have better tumor responses.

  Recruiting at 3 sites Phase 3 Akeso · Harbin, Heilongjiang and 2 other locations · NCT06953999

• ctDNA‑MRD guided Ivonescimab plus docetaxel versus standard care for advanced NSCLC after long immunotherapy benefit

  This trial tests whether adding Ivonescimab with docetaxel, guided by ctDNA minimal residual disease (MRD), can help people with advanced NSCLC who had a long benefit from first‑line immunotherapy but are now MRD‑positive.

  Recruiting Phase 2 Second Xiangya Hospital of Central South University · Changsha and 19 other locations · NCT06951646

• Ivonescimab combined with AG regimen for borderline resectable pancreatic cancer

  This study is testing if a new treatment combining Ivonescimab with standard therapy can help people with borderline resectable pancreatic cancer get ready for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06944106

• Ivonescimab for previously treated advanced clear cell kidney cancer

  This tests whether ivonescimab can shrink or control advanced clear cell kidney cancer in people whose disease progressed after at least one prior systemic treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06940518

• Ivonescimab plus docetaxel for advanced non-small cell lung cancer

  This trial tests whether adding ivonescimab to docetaxel helps people with advanced or metastatic non-small cell lung cancer that progressed after PD-(L)1 inhibitor therapy.

  Recruiting Phase 3 Akeso · Shanghai, Shanghai Municipality · NCT06928389

• Testing ivonescimab for endometrial and cervical cancers

  This study is testing a new drug called ivonescimab to see if it can help people with advanced endometrial and cervical cancers that haven't improved after other treatments.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06925724

• Combining Ivonescimab with Chemotherapy for Mesothelioma Treatment

  This study is testing if adding a new drug called ivonescimab to chemotherapy can help people with pleural mesothelioma who haven't had success with other treatments.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT06875076

• Combining ivonescimab with chemotherapy for treating colorectal cancer liver metastases

  This study is testing if adding ivonescimab to chemotherapy can help people with colorectal cancer that has spread to the liver feel better and improve their treatment results.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06848842

• Ivonescimab plus chemotherapy for advanced or metastatic gastric and gastroesophageal adenocarcinoma

  This trial tests whether adding ivonescimab to standard chemotherapy helps adults with advanced or metastatic gastric or gastroesophageal adenocarcinoma respond better to treatment.

  Recruiting at 2 sites Phase 2 Unicancer · Lyon and 3 other locations · NCT06846346

• Combining a new drug with radiation and chemotherapy for pancreatic cancer treatment

  This study is testing a new drug combined with radiation and chemotherapy to see if it helps people with locally advanced pancreatic cancer live longer without their disease getting worse.

  Recruiting Phase 1/2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06844422

• Ivonescimab for pleural mesothelioma that returned after immunotherapy and chemotherapy

  This will try ivonescimab, a bispecific antibody targeting VEGF and PD‑1, as a second- or third-line treatment for people with pleural mesothelioma whose cancer progressed after immunotherapy and standard chemotherapy.

  Recruiting at 20 sites Phase 2 Intergroupe Francophone de Cancerologie Thoracique · Besançon and 20 other locations · NCT06840834

• Evaluating Ivonescimab for advanced salivary gland cancers

  This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

• Treatment for brain metastases in triple-negative breast cancer using Ivonescimab and TROP2 ADC

  This study is testing a new combination treatment of ivonescimab and TROP2 antibody-drug conjugates for patients with triple-negative breast cancer that has spread to the brain to see if it helps them feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06793332

• Combining Ivonescimab and Cadonilimab with chemotherapy for extensive stage small cell lung cancer

  This study is testing if combining two new drugs, Ivonescimab and Cadonilimab, with chemotherapy can help people with extensive stage small cell lung cancer feel better compared to standard treatments.

  Recruiting Phase 2 Sichuan University · Chengdu, Sichuan · NCT06769971

• First-line treatment for metastatic lung cancer patients with high PD-L1 using ivonescimab

  This study is testing if a new drug called ivonescimab can help adults with advanced lung cancer who have high PD-L1 levels live longer and feel better compared to another treatment called pembrolizumab.

  Recruiting at 285 sites Phase 3 Summit Therapeutics · Chandler, Arizona and 284 other locations · NCT06767514

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

• Testing ivonescimab for recurrent glioblastoma

  This study is testing a new treatment called ivonescimab to see if it can help adults with recurrent glioblastoma feel better and manage their disease after other treatments have failed.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas and 1 other locations · NCT06672575

• Testing ivonescimab for advanced skin cancer

  This study is testing if ivonescimab can help people with advanced skin cancer feel better and control their disease.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06567314

• Ivonescimab versus FOLFOX for advanced biliary tract cancer

  This trial will test whether ivonescimab works better than standard FOLFOX chemotherapy for people with advanced biliary tract cancer after their first treatment stopped working.

  Recruiting at 17 sites Phase 2 Unicancer · Amiens and 41 other locations · NCT06529718

• Combining Ivonescimab with Radiation and Chemotherapy for Pancreatic Cancer

  This study is testing if combining a new drug called ivonescimab with radiation and chemotherapy can help people with pancreatic cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan · NCT06491472

• AK112 combined with chemotherapy for advanced esophageal cancer

  This study is testing if a new drug called AK112, when combined with chemotherapy, can help people with advanced esophageal cancer who haven't had treatment before.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06489197

• Combining SBRT, chemotherapy, and AK112 for treating luminal-type breast cancer

  This study is testing whether combining a type of radiation therapy, chemotherapy, and a new immunotherapy can help people with luminal-type breast cancer respond better to treatment.

  Recruiting Phase 2 Hubei Cancer Hospital · Wuhan, Hubei · NCT06402435

• Combination treatment for advanced gastric and gastroesophageal junction cancer

  This study is testing a new combination of two medications with chemotherapy to see if it can help adults with advanced stomach or gastroesophageal junction cancer.

  Recruiting Phase 2 Harbin Medical University · Harbin · NCT06196697

Quick answers

How many clinical trials of Ivonescimab are recruiting right now?

62, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in China (33 trials), United States (26 trials), France (6 trials), Japan (3 trials), Belgium (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 41, Phase 1/2: 12, Phase 3: 5, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →